NCT01957176 - A Rollover Study to Provide Continued Treatment With Eltrombopag | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2013

Primary Completion Date

February 23, 2022

Study Completion Date

February 23, 2022

Conditions

Thrombocytopaenia

Interventions

DRUG

Eltrombopag (ELT)

Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.

Trial Locations (13)

3000

Novartis Investigative Site, Leuven

4000

Novartis Investigative Site, Sousse

11527

Novartis Investigative Site, Athens

71201

Novartis Investigative Site, Heraklion, Crete

75571

Novartis Investigative Site, Paris

200025

Novartis Investigative Site, Shanghai

Unknown

Novartis Investigative Site, Shatin

Novartis Investigative Site, Tullamore

1081 HV

Novartis Investigative Site, Amsterdam

Lima 27

Novartis Investigative Site, San Isidro

41-500

Novartis Investigative Site, Chorzów

022328

Novartis Investigative Site, Bucharest

02841

Novartis Investigative Site, Seoul